Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • Investigational drug...

    Investigational drug Quinagolide may offer pain relief in endometriosis: Study

    Written by Dr. Kamal Kant Kohli Kohli Published On 2020-01-12T20:20:38+05:30  |  Updated On 12 Jan 2020 8:20 PM IST
    Investigational drug Quinagolide may offer pain relief in endometriosis: Study

    Endometriosis affects an estimated 176 million individuals globally. The disease is a major cause of pain, subfertility, disability and significantly compromised quality of life in those affected. Impaired bowel, urinary, sexual and reproductive functions are common, and the systemic influences of endometriosis can significantly impact the physical, mental, emotional and social well-being of those living with the condition. Definitive causes remain elusive, and there is no prevention or universal cure.


    The Endometriosis Research Center (ERC) (www.endocenter.org) reports that a new, non-hormonal medical therapy is being investigated for the potential treatment of pain associated with the disease. The RAQUEL Study (Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain), sponsored by Ferring, is a randomized, double-blind, Phase II clinical trial evaluating the efficacy of quinagolide on the reduction of moderate to severe endometriosis-related pain compared to placebo.


    Unfortunately, many individuals struggling with endometriosis face barriers to quality care outside the limited subspecialty centres exclusively focused on treating the disease. As a result, misdiagnosis, fragmented care and persistence of symptoms are common, and many patients will be subsequently placed on hormonal suppression to "manage" their ongoing pain. These suppressive medications only treat some symptoms - temporarily - and all have near-total recurrence rates. "Many of the existing suppressive options for endometriosis pain, like GnRH analogues, are contraindicated to pregnancy, have high costs and significant adverse side effects," said Michelle E. Marvel, ERC Founder and Executive Director. "Safer and more effective therapies that can eliminate the actual lesions, prevent recurrence and effectively relieve pain are desperately needed."


    Research has demonstrated that angiogenesis - the growth of new blood vessels - plays an important role in endometriosis. Given the disease's invasive capacity and proangiogenic factors, the angiogenic process is viewed as a potential target for therapeutic intervention. Quinagolide, a non-ergot, selective dopamine-2 receptor agonist, may diminish Vascular Endothelial Growth Factor (VEGF), a potent angiogenic factor, and result in a reduction in the levels of interleukin-6 (IL-6) as well, which is related to the pathogenesis and clinical severity of the disease. Quinagolide has demonstrated an acceptable safety profile in early studies and, unlike some of the currently available suppressive medications promoted for endometriosis pain, does not affect pregnancy and has no teratogenic effects.


    "Treatment options for endometriosis and pelvic pain are very limited. The currently available medical treatments for endometriosis all use a relatively crude approach of suppressing a woman's estrogen. Unfortunately, endometriosis in some cases produces its own estrogen, rendering the medical treatments ineffective," said Andrew Cook, M.D., an endometriosis specialist with centres in California and Colorado (www.VitalHealth.com). "Optimal surgical treatment requires highly specialized, wide excision of the endometriosis implants, essentially requiring a similar approach to that of cancer surgery, as there is no adjunct treatment to eliminate any disease left behind at surgery. This novel and a new approach may provide a new avenue of treatment of endometriosis, either alone or in combination with surgery to eliminate any remaining microscopic disease, with the potential benefit of increasing treatment success rates and decreasing recurrence rates."


    Sponsored by Ferring, the RAQUEL study seeks to evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on the reduction of moderate to severe endometriosis-related pain. Individuals who have been surgically diagnosed with the disease who may wish to participate can learn more about the study and inclusion criteria at www.researchmyendo.com.
    endometriosisEndometriosis Research Centerinvestigational drugpain reliefQuinagolide
    Source : Endometriosis Research Center

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok